The different pocket proteins are established as negative cell cycle regulators. With regard to the repressor functions of pocket proteins in cellular senescence, studies so far have mainly focused on pRb/p105. Here, we show that in a broad range of wild-type p53-expressing human tumor cells, and in human diploid fibroblasts, Rb2/p130 is the dominating pocket protein in replicative and in accelerated senescence. Senescent cells are arrested at the transition from late G1-to early S-phase, as indicated by the absence of S-and G2-phase cyclins A and B. Expression of cyclin A and entry into S-phase resumed after RNA interference-mediated knockdown of Rb2/ p130. Activation of different upstream pathways by overexpression of either p21 or p16 converged on Rb2/ p130 accumulation and induced senescence. In contrast, p53-or p21-negative cells treated with DNA-damaging agents failed to accumulate Rb2/p130 and to enter senescence. Our data suggest that Rb2/p130 is a member of the p53-p21 DNA damage signaling cascade, and represents the essential pocket protein family member needed for the induction of any type of senescence.
Introduction
Cellular senescence is characterized by an irreversible proliferation arrest in G1-phase of the cell cycle, which is triggered by oncogenic signaling, genotoxic agents, inadequate growth conditions and telomere shortening. All these different kinds of stress induce DNA damage and activate the DNA damage response kinases ATM, ATR, Chk1 and Chk2, which phosphorylate and thereby activate the tumor suppressor protein, p53. Activation of p53 transactivates the cdk inhibitor, p21, and leads to a subsequent accumulation of pocket proteins. A continuous activation of p53 and pocket proteins, and their pathways provokes the formation of senescence-associated DNA damage foci that are resistant to repair and enriched in g-H2AX and p53BP1. This common feature led to a new definition of senescence as a specific cell cycle arrest with persistent DNA damage signaling (Mallette and Ferbeyre, 2007) . Senescent cells are viable but lose the ability to divide, change their phenotype and exhibit an altered gene expression profile. Two proteins that often show an increased expression in senescent cells are the cdk inhibitors, p21 and p16. Both are components of tumor suppressor pathways governed by p53 and the pocket proteins. With regard to the requirement of these cdk inhibitors for induction and maintenance of cellular senescence, different results have been published. In some experiments the p16-pRb signaling pathway accounted for the induction and maintenance of irreversible growth arrest (Beausejour et al., 2003; Narita et al., 2003) , whereas others showed that the p53-p21 signaling cascade is sufficient to arrest cells irreversibly in senescence (Gire and Wynford-Thomas, 1998; Chang et al., 2000; Kapic et al., 2006) . As p53-p21 signaling activates the pocket protein family, an efficient induction of senescence through this pathway depends on a functional pocket protein.
The pocket protein family consists of three members, namely pRb/p105, p107 and Rb2/p130. Each pocket protein can associate with a distinct subgroup of the E2F transcription factor family. pRb/p105 inhibits the transcriptional activators E2F-1/-2/-3, whereas p107 and Rb2/p130 interact with the transcriptional repressors E2F-4/-5. The main function of pocket proteins in cell cycle regulation is to bind and negatively regulate E2F transcription factors. RB/E2F complexes can only form when pocket proteins are present in the hypophosphorylated form. Cdk inhibitors prevent the phosphorylation of pocket proteins by inactivation of cyclin/cdk complexes, and thus sustain the maintenance of RB/E2F complexes.
So far, studies on pocket proteins in cellular senescence mainly focus on pRb/p105, indicating that a functional pRb/p105 is needed to induce a G1-phase arrest (Beausejour et al., 2003; Narita et al., 2003; Psyrri et al., 2004; Takahashi et al., 2006) . This corresponds to the note that pRb/p105 impairs progression from G1-into S-phase by repressing the promoters of cyclin E and cyclin A (Zhang et al., 2000) . In contrast, functions of Rb2/p130 have been mainly associated with maintenance of quiescence. However, there is evidence that Rb2/p130 can also exert substantial functions in negative control of G1-to S-phase progression. For instance, overexpression of Rb2/p130 in three different cell lines induced a G1-phase arrest. Two of these cell lines did not respond with a G1 arrest when pRb/p105 was overexpressed (Zhu et al., 1993; Claudio et al., 1994; Lacy and Whyte, 1997) . The central function of Rb2/p130 in a G1-phase arrest is presumably the negative regulation of the cyclin A promoter. Recent publications have shown that Rb2/p130 is highly elevated after induction of cellular senescence in a rat glioblastoma cell line (Kapic et al., 2006) and in a human mammary carcinoma cell line (Jackson and Pereira-Smith, 2006) , whereas pRb/p105 and p107 are significantly downregulated. The relevance of these new findings with respect to different cell systems and different species has still to be proven.
The divergent data prompted us to determine the function of Rb2/p130 in induction and maintenance of cellular senescence in more detail. Here, we report that independent of the p16 status, the induction of replicative and accelerated senescence depends on the accumulation of hypophosphorylated Rb2/p130. We hypothesize that Rb2/p130 is a member of the p53-p21 DNA damage signaling cascade, which is needed for efficient induction of any type of senescence.
Results
Rb2/p130 is the characteristic pocket protein accumulating in accelerated senescence DNA damage-induced senescence was studied in five human tumor cell lines originating from different tissues (A172, U87/glioblastoma, HCT116/colon carcinoma, MCF7/mammary carcinoma and U2OS/osteosarcoma). These cell lines have an inactivated INK4A locus, impairing the expression of p16 and p14 ARF , and retained a functional wild-type p53. Asynchronously growing cells were treated with empirically established doses of either g-irradiation (20 Gy) or the topoisomerase-II inhibitor, doxorubicin (1 mM, 2 h), to induce DNA double strand breaks. The changes in phenotype and cell cycle distribution were monitored 7 days after the treatment. Independent of the DNA-damaging treatment, the cells could be kept in culture for a long time, were viable but did not divide and showed no signs of apoptosis, indicating a permanent growth arrest. Microscopic analysis revealed that after induction of DNA damage, all five cell lines adopted a senescent phenotype with a large, flattened shape and multiple or enlarged nuclei (Figure 1a) , and enhanced the expression of SA-b-galactosidase (Figure 1b) , which is typical for senescent cells (Dimri et al., 1995) . Western blot analysis confirmed the induction of a G1-phase arrest: the S-and G2-phase cyclins A and B were downregulated to almost undetectable levels, whereas the expression of the G1-phase cyclins D and E was constant or even enhanced (Figure 2a ). In addition, expression of the transcription factor E2F-1, which is necessary for transactivation of cell cycle-promoting genes, was strongly decreased. As expected, DNA damage induced accumulation of p53 and its target gene product p21. With regard to the different pocket proteins, Rb2/p130, which was expressed in small amounts in untreated cells, shifted to its hypophosphorylated form and accumulated in high amounts 7 days after DNA-damaging treatment. The two other pocket proteins, pRb/p105 and p107, which were strongly expressed in cycling cells, showed a drastic reduction in their expression level to hardly detectable amounts. The small amounts of pRb/p105 that were still detectable 7 days after treatment were present in a hypophosphorylated form. Treatment with DNAdamaging agents altered the cell cycle profiles of all human tumor cell lines assayed (Figure 2b ), arresting cells with both 2 and 4 N DNA content. Microscopic analysis of senescent cells indicated the presence of cells with enlarged or multiple nuclei (Figure 1a ), which could contribute to the population of 4 N cells. To exclude ongoing DNA replication, treated cells were assayed for S-phase activity by microscopic analysis of BrdU incorporation. Quantification of BrdU-positive cells showed that DNA damaged cells strongly reduced the incorporation of BrdU, confirming the absence of S-phase activity (Figure 2b) .
Thus, induction of cellular senescence in wild-type p53-expressing, p16-negative human tumor cells is characterized by an accumulation of p53, p21 and hypophosphorylated Rb2/p130. Neither accumulation of pRb/p105 nor p16 seems to be required for the establishment of senescence.
Overexpression of p16 or p21 causes accumulation of Rb2/p130 and senescence To investigate whether the cdk inhibitors, p16 and p21, induce cellular senescence by activating pathways involving different pocket proteins, either p16 or p21 were expressed in MCF7 cells. As a control, cells were transfected with an empty vector. Transfected cells were selected 7 days by antibiotic resistance. Microscopic analysis revealed that control cells formed a stably proliferating population, whereas cells transfected with the cdk inhibitors, p16 or p21, stopped proliferation and adopted a senescent morphology (Figure 3a) . Flow cytometry data confirmed proliferation of control cells and induction of a G1-phase arrest in cells expressing exogenous p16 or p21 (Figure 3b ). With regard to the protein expression pattern of cyclins, all cyclins were expressed in control cells (Figure 3c ). Cells with ectopic p21 showed a marked decline in the protein level of cyclin A and B, as observed after DNAdamaging treatment. In further concordance with our results, the expression of p21 led to a distinct decrease in pRb/p105 and p107, whereas Rb2/p130 expression was retained (Figure 3c ). Overexpression of p16 induced similar changes in the protein expression pattern (Figure 3c ). These data show that, independent of the cdk inhibitor inducing the G1 arrest, the same signaling cascade is activated, leading to accumulation of Rb2/p130. p53 and p21 are required for accumulation of Rb2/p130 and induction of senescence To prove the direct relation among p53 activation, p21 transactivation, Rb2/p130 accumulation and subsequent induction of a terminal growth arrest, we used the HCT116 cell line and its isogenic derivatives in which both alleles of either p53 or p21 are disrupted. We treated the cell lines with doxorubicin and performed a time course experiment to observe changes in phenotype and cell cycle. The flow cytometry data ( Figure 4a) show that HCT116 cells arrested with a 2 and 4 N DNA content 1 day after treatment and remained in this arrest for at least 5 days. HCT116 p53
À/À cells showed a peak of 4 N cells at day 1, but a sustained arrest in either G1-or G2-phase could not be achieved. Instead, the whole cell population accumulated in sub-G1, indicating cell death. Similarly, HCT116 cells negative for the p53 downstream target p21 could not permanently arrest after DNA damage but also died. Pictures of cells at day 5 ( Figure 4b ) prove that in contrast to parental HCT116 cells, which were viable and exhibited a senescent phenotype, p53-and p21-negative HCT116 cell cultures revealed signs of massive cell death after DNA-damaging treatment. These data show that p53-mediated upregulation of p21 is necessary to induce a stable cell cycle arrest. Samples up to day 3 after treatment were analyzed by western blot to investigate the connection between activation of the DNA damage signaling cascade and accumulation of Rb2/p130. Samples obtained on day 5 were excluded as no representative protein pattern could be expected for the dying cell populations. Parental HCT116 cells accumulated cyclin D and E after DNA damage, whereas cyclin A and B declined. Expression of pRb/p105 and p107 was downregulated, whereas Rb2/p130 accumulated. p53 as sensor of DNA damage was activated and p21 levels strongly increased ( Figure 4c ). In contrast, no distinct changes in the cyclin expression pattern could be observed in HCT116 p53 À/À and HCT116 p21 À/À cells after treatment. Importantly, p53-or p21-negative cells were not capable of accumulating either Rb2/p130 or another pocket protein in the hypophosphorylated form in response to DNA damage (Figure 4c ). The accumulation of Rb2/p130 as a result of an activated DNA damage signaling cascade, therefore, seems to be a prerequisite for induction of cellular senescence and is dependent on functional p53 and p21.
Rb2/p130 is essential for an efficient G1 arrest and induction of senescence To determine the necessity of Rb2/p130 in induction and maintenance of accelerated senescence, we infected A172 cells with lentiviral particles coding for either scr or Rb2/p130-specific short hairpin (shRNA). By antibiotic selection, stably proliferating populations were established for both shRNAs. These cells were then treated with doxorubicin, analyzed 6 days later by western blot and compared with non-treated cells. Nondamaged cells showed an efficient suppression of Rb2/ p130 by the specific shRNA, whereas no major changes in other cell cycle regulating genes were obvious (Figure 5a ). After DNA-damaging treatment, the Rb2/ p130 shRNA-expressing cells did not completely downregulate pRb/p105 and p107, and even expressed hyperphosphorylated pRb/p105. Apparently, efficient downregulation of these two pocket proteins is dependent on the accumulation of hypophosphorylated Rb2/ p130. Similarly, the suppression of cyclin A expression in drug-treated cells seems to depend on functions of Rb2/p130, as significant levels of cyclin A were still detectable after treatment in Rb2/p130-deficient cells. In accordance, flow cytometry of Rb2 shRNA-expressing cultures shows that the proportion of G1 cells declined and cells accumulated in S/G2-phase after DNA damage. In contrast, scr shRNA-expressing cultures showed a prominent G1 peak and a strong reduction in the proportion of S-phase cells (Figure 5b ). In these cells, S-phase activity assayed by BrdU pulse labeling was no longer detectable after 2 days, whereas it only declined gradually in Rb2 shRNA-expressing cultures (Figure 5c ). Conversely, the proportion of SA-b-galpositive cells increased in DNA damaged control cells (Figure 5d ), whereas only a minor population of Rb2 shRNA-expressing cultures showed this marker. These data indicate that Rb2/p130 contributes to the senescence response to DNA damage in A172 cells.
Rb2/p130 accumulation after DNA-damaging treatment is also observed in human diploid fibroblasts The five different tumor cell lines used for the previous experiments have acquired various genetic alterations during carcinogenesis. They have in common that they do not express the cdk inhibitor p16 and its related protein p14
ARF . Thus, the activation of a signaling pathway involving Rb2/p130 after DNA damage could be specific for p16-negative cells. To test whether normal diploid cells respond differently to DNA-damaging treatment, we used IMR90 and WI38 human diploid fibroblasts and treated them with the same doses of doxorubicin or g-irradiation as were used for the treatment of tumor cells. At 7 days after treatment, the cells were analyzed by western blot and flow cytometry. The data show that DNA damage induced similar protein expression changes in human diploid fibroblasts as were observed in tumor cells (Figure 6a ). The cells exhibited a clear downregulation of cyclin A and B, a strong decrease in protein levels of p107 and pRb/p105 and an accumulation of Rb2/p130. Protein levels of p21 increased in both cell lines, whereas only IMR90 accumulated p16. With regard to the cell cycle profile, human diploid fibroblasts were arrested with a DNA content of 2 and 4 N, as observed for the treated tumor cells (Figure 6b ). We conclude that the accumulation of Rb2/p130 after DNA damage and subsequent induction of cellular senescence is independent of the p16 status of a cell.
Rb2/p130 is also retained in replicative senescence To investigate the relevance of Rb2/p130 in replicative senescence, we cultivated IMR90 and WI38 cells from early to late passages. The protein expression analysis by western blot showed that the levels of pRb/p105 and p107 declined to a nearly undetectable level in replicative senescence, whereas the amounts of Rb2/ p130 remained the same in exponentially growing and senescent cultures (Figure 7a ). At the end of their proliferative life span, human diploid fibroblasts arrested at G1-to S-phase transition were indicated by the downregulation of the S-and G2-phase cyclins A and B. The G1-phase cyclins D and E were expressed to the same extent in senescent as in exponentially growing cultures (Figure 7a ). In agreement with the protein expression data, senescent cells showed a G1/S-phase arrest in flow cytometry (Figure 7b) . The cdk inhibitors, p21 and p16, were present in senescent cells, but no uniform changes could be observed from early to late passage cells. Our data show that the changes in pocket protein expression after DNA damaging treatment are also typical of replicative senescence.
To determine whether suppression of Rb2/p130 in diploid fibroblasts would itself be sufficient to abrogate replicative senescence, we transduced IMR90 (passage 14), MRC5 (passage 7) and primary human skin fibroblasts (passage 11) with scr-and Rb2-specific shRNA, and selected for stably expressing cells.
Scr shRNA-expressing cultures, proliferating at the same rate as the maternal cell populations, could readily be established, but no proliferating cultures were obtained with Rb2-specific shRNA (data not shown). It indicates that suppression of Rb2/p130 affects basic control functions in proliferation, which are indispensable in normal diploid fibroblasts.
Discussion
Essential members of the senescence signaling pathway Although an efficient activation of senescence is well known to rely on a functional pocket protein pathway, the individual role of the different pocket proteins in this process is still uncertain. For instance, some data claim that pRb/p105 is of primary importance to stall cells in a senescent arrest (Beausejour et al., 2003; Narita et al., 2003; Psyrri et al., 2004; Takahashi et al., 2006) . However, experiments of Narita et al. (2003) reveal that knockdown of pRb/p105 by shRNA is not sufficient to Figure 5 Rb2/p130 is needed to efficiently suppress the transition from G1-to S-phase of DNA damaged cells. A172 cells were infected with lentiviral particles for scr or Rb2/p130 shRNA. A stable population of shRNA-expressing cells was selected by antibiotic resistance at least over 2 weeks. Cells then were treated with 1 mM doxorubicin (D) and compared with non-treated cells (ctrl). Western blot analysis shows that a clear downregulation of Rb2/p130 can be achieved by the specific shRNA. These cultures do not efficiently downregulate pRb/p105 and p107, and still express cyclin A 6 days after DNA-damaging treatment, indicating S-phase activity. Inactive, hyperphosphorylated pRb/p105 is still detectable (a). The proportion of Rb2-suppressed cells in G1/S-phase decreases to the benefit of S/G2 after DNA damage (b). Rb2-suppressed cells incorporate BrdU at a longer time period (c, 20 fields, each comprising 50 cells, were microscopically assayed in duplicate at each time point), and become SA-b-gal positive only at a low rate 6 days after treatment (d, cultures were grown in 6-well plates and 10 fields, each comprising 100-200 cells, were assayed in duplicate at each time point).
prevent senescence, whereas transfection of an E1A mutant that inactivates the entire pocket protein family clearly upregulates cyclin A expression and increases S-phase activity. This already indicates that other pocket proteins may contribute to induction of a senescence arrest.
Our data obtained with different human cell lines show that pRb/p105 and p107 are clearly downregulated in senescent cells implying that accumulation of these proteins is not required in this pathway. In contrast, Rb2/p130 accumulates in high amounts and proves to be the dominating pocket protein in accelerated and replicative senescence, pointing to a general role of Rb2/p130 in this arrest. Accordingly, suppression of Rb2/p130 in A172 cells abolishes the G1/S-phase block, leads to cyclin A expression and extends S-phase activity after DNA damage. We had no evidence for a mutual compensation of pocket proteins in A172 cells, as was suggested for MCF7 cells (Jackson and Pereira-Smith, 2006) . This difference may result from a different genetic background. Further studies are needed to unravel the interplay of the pocket proteins in induction of senescence.
The efficient induction of senescence is dependent on a functional DNA damage response. Accordingly, p53
À/À cells escape a cell cycle arrest after DNAdamaging treatment and undergo apoptosis (Waldman et al., 1996; Brown et al., 1997; Bunz et al., 1998) . Furthermore, knockdown of p53 by shRNA impairs oncogene-induced senescence (Di Micco et al., 2006) .
Our data now show that the p53-mediated transactivation of p21 is required for accumulation of hypophosphorylated Rb2/p130, linking Rb2/p130 functions tightly to the p53-p21 DNA damage response pathway. Disruption of this pathway either by loss of p53 or p21 blocked downregulation of cyclin A and B, prevented accumulation of Rb2/p130 and impaired induction of senescence (see also Supplementary Figure 1) . Conversely, ectopic expression of p21 was sufficient to induce accumulation of Rb2/p130 and to provoke a senescent phenotype. With regard to the cdk inhibitor p16, our experiments revealed that functions of this inhibitor are not necessarily required for cellular senescence, as we could effectively induce senescence in different p16-negative tumor cell lines, which is in line with previous observations (Gire and Wynford-Thomas, 1998; Chang et al., 2000; Kapic et al., 2006) . However, ectopic expression of p16 also converged on an accumulation of Rb2/p130 and induced senescence, emphasizing a general function of Rb2/p130 in cellular senescence.
Our data led to the conclusion that DNA damage entails an accumulation of active, hypophosphorylated Rb2/p130 through activation of p53 and p21. Thus, Rb2/p130 can be considered as a constituent of the DNA damage response pathway and its growth suppressive functions in this response rely on a functional p53, known as central mediator of senescence.
Regulation of cyclin and pocket protein expression in senescence Some functions of Rb2/p130 described for quiescent cells predestine this protein to be the dominant pocket protein in senescence also. Promoter-binding studies of quiescent cells showed that hypophosphorylated Rb2/ p130 in complex with E2F-4 represses most E2F-responsive promoters, including promoters of genes which are critically required to proceed into and through S-phase, namely cyclin A, p107 and E2F-1 (Takahashi et al., 2000; Ren et al., 2002; Araki et al., 2003) . By decreasing the expression of the basal transcription factor E2F-1, Rb2/p130 indirectly prevents transcription of E2F-1-regulated genes, which can also affect pRb/p105 and p107 expression, as transactivation of their promoters depends on E2F-1 activity (Shan et al., 1994; Takahashi et al., 2000) .
We assume that the promoter-binding sites of Rb2/ E2F-4 repressor complexes in quiescent and senescent cells are mainly the same. Functions of Rb2/p130 in quiescence are exactly in line with the observations that we made in senescent cells, in which expression of cyclin A, pRb/p105, p107 and E2F-1 is strongly decreased. The binding of Rb2/p130 to the cyclin A promoter in senescent cells was already proven in rat (Kapic et al., 2006) and in human tumor cells (Jackson and PereiraSmith, 2006) . In the latter, Rb2/p130 repressor complexes could also be detected at the cyclin B promoter. Unable to express the S-and G2-phase cyclins, cells in our studies arrest during transition from late G1 to early S-phase. Our RNA interference experiments also reveal that the suppression of cyclin A expression by Rb2/p130 is essential to prevent progression of DNA damaged cells into S-phase. With regard to pRb/p105 and p107, the direct or indirect repressor functions of Rb2/p130 at their promoters explain the dominating function of Rb2/ p130 in senescence.
The difference in reversibility of these two arrest forms is rather the result of different upstream signals inducing the arrest. Quiescence is induced in response to suboptimal nutritional conditions and the arrest can be reverted on mitogenic stimulation (Pardee, 1974) . In senescence, mitogenic signals are present, but cells are irreversibly arrested due to severe DNA damage. The persistent DNA damage signaling is probably the reason for the permanent binding of Rb2/E2F-4-repressor complexes to their target promoters, which recruit chromatin-modifying enzymes , leading to effective silencing by means of chromatin remodeling.
Importance of Rb2/p130 in tumor suppression and cancer therapy Senescence can prevent oncogenic transformation and therefore acts as a barrier in early tumor development (Braig et al., 2005; Chen et al., 2005; Collado et al., 2005) . Furthermore, senescence is also a common response to DNA-damaging chemotherapy or g-irradiation, both in vitro and in vivo (Chang et al., 1999; Schmitt et al., 2002; te Poele et al., 2002) . Therefore, inactivation of Rb2/p130 as a member of the senescenceinducing signaling cascade could promote tumor progression or favor the emergence of recidives after cancer treatment. However, until now, little is known about the correlation between inactivation of Rb2/p130 and tumor development. It has been observed that low levels of Rb2/p130 expression correlate with high malignancy in primary tumors (Susini et al., 2001; Li et al., 2004) , but only some cases of mutations or promoter methylations of Rb2/p130 have been published (Cinti et al., 2005; Tosi et al., 2005) . Unlike direct genetic or epigenetic inactivation, functional inactivation of signaling pathways involving Rb2/p130 occurs at high frequency in tumor development. Rb2/p130 is inactivated by viral oncogenes, such as HPV E7, adenoviral E1A or SV40 LT (Cobrinik et al., 1993; Zalvide and DeCaprio, 1995; Zhang et al., 2006) . Moreover, genes at nodal points of growth arrest pathways, such as ATM or p53, are frequent targets of mutations in cancer cells (Khanna, 2000; Olivier et al., 2002) and disrupt signaling to Rb2/p130. The Rb2/p130-controlled G1/S checkpoint is also deregulated by other common events in tumorigenesis, such as overexpression of cyclin D or E, cdk4, or loss of cdk inhibitors, such as p21 (through p53 mutation), p15, p16 or p27 (Malumbres and Barbacid, 2001) .
Our data clearly show that induction of a stable cell cycle arrest by Rb2/p130 depends on an intact upstream signaling cascade. Conversely, our work also proves that, at least in cell culture, absence of Rb2/p130 bears the risk of improper cell cycle control in late G1/early S-phase in presence of serious DNA damage. Understanding this DNA damage signaling cascade involved in induction of senescence may help to predict the outcome of certain cancer therapies against the specific genetic background of a patient.
Materials and methods

Cell culture
The following cell lines were used: A172, U87 (ECACC, Salisbury, UK), WI38 (ATCC, LGC Promochem, Wesel, Germany), HCT116, IMR90, MCF7, MRC5, U2OS (CCS, Hamburg, Germany) and primary human skin fibroblasts.
HCT116 p53
À/À and p21 À/À were a gift from B. Vogelstein (MD, USA). Cells were grown in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, Karlsruhe, Germany), supplemented with 5% fetal calf serum (FCS) (PAA, Pasching, Austria). To induce DNA damage, cells were either incubated with 1 mM doxorubicin for 2 h (Pharmacia, Karlsruhe, Germany) or irradiated with 20 Gy g-radiation. BrdU incorporation was done for 40 min with 10 mM BrdU (Sigma Aldrich, Munich, Germany) in DMEM.
Antibodies and expression plasmids
The following antibodies were used: Bu20a (BrdU), E6H4 (p16) (Dako, Glostrup, Denmark), mAb245 (pRb/p105) (Biomol, Hamburg, Germany), Clone 10 (Rb2/p130) (BD Biosciences, CA, USA), K-19 (HSC70), H-432 (cyclin A), GNS1 (cyclin B), H-295 (cyclin D), HE12 (cyclin E), C-18 (p107), KH95 (E2F-1), FL-393 (goat) (p53), F-5 (p21) (Santa Cruz Biotechnology, CA, USA) and Ab-1 (b-tubulin) (Oncogene Research, CA, USA). Plasmids used for production of lentiviral particles were: for scr shRNA MISSION-Non-Target shRNA Control Vector SHC002, for Rb2/p130 shRNA MISSIONshRNA TRCN0000039924 NM_005611.2-2840s1c1, for pRb/ p105 shRNA MISSION-shRNA TRCN0000040163 NM_000321.1-4075s1c1 (Sigma Aldrich), packaging vector pCMV-dR8.91 and envelope vector pMD2G (Tronolab, Lausanne, Switzerland). Plasmids used for protein expression were: pcDNA3 (Invitrogen), pcDNA3-p21 (coding sequence of human p21 CIP1/WAF1 cloned into pcDNA3 by HindIII and XhoI), pcDNA3-p16 (coding sequence of human 16
INK4a cloned into pcDNA3 by HindIII and XhoI).
Transfections and infections
For production of lentiviral particles from MISSION-shRNA vectors, HEK293T cells were transfected at 50% confluency. For every 100 mm dish, 45 ml PEI (1 mg/ml) were added to 3 mg of shRNA vector, 2.7 mg pCMV-dR8.91 and 0.3 mg pMD2G in 1 ml of OptiMEM (Invitrogen), vortexed and incubated for 10 min. The mixture was added dropwise to cells cultured in 3 ml OptiMEM. After 6 h, the medium was exchanged for 5 ml DMEM þ 10% FCS. 48 h later, viral particles were harvested. For infecting A172 cells, 500 ml of virus suspension was added to 50% confluent cultures in 60 mm dishes containing 1 ml DMEM þ 5% FCS. After 24 h, medium was exchanged for puromycin-containing medium (3 mg/ml, Sigma Aldrich) to obtain cells stably expressing the shRNA construct.
For protein expression, MCF7 cells were transfected at 50% confluency. Transfection was done using Effectene (Qiagen, Hilden, Germany). For every 60 mm dish, 1-mg DNA was diluted with buffer EC to a final volume of 150 ml. A total of 8 ml of enhancer was added, mixed by vortexing and incubated for 5 min at room temperature. In total 125 ml Effectene was added, mixed by vortexing and incubated for 15 min at room temperature. The mixture was added dropwise to cells cultured in 4 ml DMEM þ 5% FCS. At 24 h after transfection, medium was exchanged for G418-containing DMEM (800 mg/ml, Invitrogen) plus 5% FCS. Cells were assayed 7 days after transfection.
Immunofluorescence Cells were grown on glass coverslips and fixed in À20 1C acetone for 2 h. Fixed cells were rehydrated in phosphate-buffered saline (PBS) for 10 min. For detection of BrdU, cells were treated with 2 N HCl (37 1C, 10 min) before blocking with 2% donkey normal serum. Samples were then incubated with the primary antibody for 30 min and with an Alexa Fluor secondary antibody (Invitrogen) for 20 min. DNA was stained using DAPI (4',6-diamidino-2-phenylindole) (Sigma Aldrich). Photographs were acquired with Leica DMRA microscope (Leica, Wetzlar, Germany).
SA-b-gal assay
Cells were fixed using 2% (v/v) formaldehyde in PBS for 10 min, washed twice using PBS and incubated with X-gal staining solution (pH 6.0) at 37 1C for at least 10 h (Dimri et al., 1995) . Color photographs of stained cells were acquired in bright field mode.
Cell cycle analysis Cells were grown in 100 mm Petri dishes, trypsinized, washed once with PBS/EDTA (0.1% w/v), resuspended in 0.6 ml PBS/ EDTA and fixed using 1.4 ml methanol (À20 1C). After rehydration in PBS/EDTA, cells were suspended in 1 ml propidium iodide solution (30 mg propidium iodide; 0.3 mg RNase A per ml PBS) for 30 min at 37 1C. Labeled cells were run through a Coulter Counter (Beckman Coulter, FL, USA), or a BD FACScanto (Becton Dickinson, CA, USA). Graphs were depicted using WinMDI 2.8 software.
Western blotting Cells were trypsinized and pelleted (300 g, 10 min, 4 1C). Pellets were lysed in 50-200 ml of 2% sodium dodecyl sulfate sample buffer, sonicated and centrifuged (10 min, 13 000 g). Equal amounts of protein were loaded onto 8 or 13% polyacrylamide gels, electrophoresed and blotted onto nitrocellulose (Hybond) (Amersham, Buckinghamshire, UK). The membrane was blocked in 5% nonfat dried milk in Tris-buffered saline tween-20. Proteins were detected using appropriate primary antibodies and secondary antibodies conjugated with peroxidase (Biomol) diluted in 5% nonfat dried milk in Tris-buffered saline tween-20. Bound peroxidase was detected using ECL and visualized by exposing the membrane to X-ray films.
